ProPhase Labs, Inc. Contractual Obligation
ProPhase Labs, Inc. (PRPH) had Contractual Obligation of $4.36 million as of 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligation · last filed 2022-11-10
- 2022-09-30: Contractual Obligation $4.36M.
- 2022-06-30: Contractual Obligation $6.24M.
- 2022-03-31: Contractual Obligation $3.21M.
- 2021-12-31: Contractual Obligation $3.38M.
| Period end | Contractual Obligation |
|---|---|
| 2022-09-30 | $4.36M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $6.24M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $3.21M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $3.38M 10-K · filed 2022-03-31 |
| 2014-09-30 | $1.84M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $1.88M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $1.88M 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |